Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen to Pay up to $17.6M for Protein-Prep Assets of LumiCyte, SuNyx

NEW YORK, Aug. 1 (GenomeWeb News) - Qiagen said today that it plans to acquire assets from LumiCyte and SuNyx, two firms providing protein sample-preparation technology for MALDI mass spectrometry.

 

Qiagen will pay up to $16 million for "key assets" from LumiCyte, including its Surface Tension Segmented biochips for MALDI mass spectrometry. Initially, Qiagen will pay $3 million in cash, followed by $4 million after 18 months and $5 million after 30 months, depending on whether financial targets are met. In addition, Qiagen may make a milestone payment of $4 million after 60 months.

 

SuNyx provides two sample-preparation platforms for liquid chromatrography MALDI mass spectrometry called MPep  and MProtChip. Qiagen will pay up to $1.6 million in total for these assets, $800,000 initially and another $800,000 depending on certain milestones.

 

Qiagen said it will provide further details on the acquisitions in its second-quarter earnings conference call on Aug. 9.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.